Low-dose rivaroxaban also reduced platelet activation and inflammation via the inhibition of the binding of FXa towards protease-activated receptors on platelet surfaces [93], possibly ameliorating the pro-thrombotic state in patients with diabetes with no indication for a full anticoagulant dose. The gene discussed is F10; the disease is diabetes mellitus.